Could it be VEXAS?

Hippolyte Guerineau; Milena Kohn; Antoine Al Hamoud; Jacques Sellier; Jennifer Osman; Aurélie Cabannes-Hamy

doi:10.1007/s00277-024-05750-8

Could it be VEXAS?

Ann Hematol. 2024 Jun;103(6):2169-2171. doi: 10.1007/s00277-024-05750-8. Epub 2024 Apr 9.

Authors

Hippolyte Guerineau¹, Milena Kohn², Antoine Al Hamoud², Jacques Sellier³, Jennifer Osman⁴, Aurélie Cabannes-Hamy²

Affiliations

¹ Department of Hematobiology, CH de Versailles, Le Chesnay, France. hguerineau@ght78sud.fr.
² Department of Hematology and Oncology, CH de Versailles, Le Chesnay, France.
³ Department of Radiology, CH de Versailles, Le Chesnay, France.
⁴ Department of Hematobiology, CH de Versailles, Le Chesnay, France.

PMID: 38589717
DOI: 10.1007/s00277-024-05750-8

Abstract

We report the case of the youngest patient described with VEXAS syndrome associated with MDS-IB1, successfully treated with azacitidine-venetoclax and allogeneic stem cell transplant.

Keywords: Allograft; Myelodysplasia; UBA1; Vexas.

Publication types

Case Reports

MeSH terms

Allografts
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Azacitidine* / therapeutic use
Bridged Bicyclo Compounds, Heterocyclic / therapeutic use
Hematopoietic Stem Cell Transplantation
Humans
Male
Myelodysplastic Syndromes* / complications
Myelodysplastic Syndromes* / drug therapy
Myelodysplastic Syndromes* / therapy
Transplantation, Homologous

Substances

Azacitidine
Bridged Bicyclo Compounds, Heterocyclic